AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery
HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.
Tata Group, a $165 billion Indian conglomerate, is set to build a medical school in the southern technology hub of Bengaluru by partnering.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)